BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
Key Highlights
- ➤Q3 total revenue $353.2 million, versus $120.7 million a year earlier
- ➤Attruby U.S. net product revenue $253.2 million, up approximately $145 million year over year
- ➤Cash, cash equivalents and marketable securities reached $1.5 billion
- ➤RECLAIM-HP dosed its first participant; topline data expected early 2028
- ➤BBP-418 PDUFA date set for November 27, 2026, with Priority Review
Expert Statements
Neil Kumar, Chief Executive Officer of BridgeBio
“I’m heartened by how consistently the evidence for acoramidis keeps pointing in the same direction. This quarter we added two more large real-world comparisons to a growing body of data showing acoramidis outperforming tafamidis on the outcomes that matter most to patients: survival and hospitalizations. This is exactly what you would expect from the only near-complete stabilizer on the market, and it is deeply gratifying to see it borne out in the real world. This is also a particularly special moment for the company. Three PDUFA dates fall within the next seven months, each with the potential to be a first for communities that have waited far too long: BBP-418 for LGMD2I/R9, where no approved therapy exists; infigratinib as the first oral option for achondroplasia; and encaleret for ADH1, which has never had a therapy of its own.”
Matt Outten, Chief Commercial Officer of BridgeBio
“Attruby delivered another quarter of sequential growth, driven by continued gains in first-line share, and the real-world evidence emerging across independent datasets continues to reinforce its position as the stabilizer of choice. This is a pivotal moment for BridgeBio as we stand weeks away from the potential approval of BBP-418, the first and only treatment for LGMD2I/R9, followed by infigratinib in February and encaleret in May. Our field teams for all three programs are hired and ready to serve these communities from day one.”
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from operations was $11.6 million, driven by increased revenue and a one-time $75.0 million BEYONTTRA sales milestone from Bayer. Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026, fully funding all three launches and expansion indications
- Attruby growth was again led by the treatment-naïve segment, with both the number of newly diagnosed patients starting treatment and Attruby's share of those starts increasing
Get started
Create a free account to read the full story.